We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Viscoelastic Heart Patch Treats Myocardial Infarction

By HospiMedica International staff writers
Posted on 01 May 2019
An adhesive epicardial patch could increase the mechanical integrity of damaged left ventricular tissues following a heart attack, claims a new study.

Developed by researchers at Brown University (Providence, RI, USA), Fudan University (Shanghai, China), Soochow University (Suzhou, China), and other institutions, the ionically crosslinked transparent gel-point adhesive patch (GPAP) is a viscoelastic material that combines both fluid and solid properties. More...
The fluid properties are retained up to a certain amount of stress, at which point the material solidifies and turns stiffer, which can accommodate the cyclic deformation of the myocardium and left ventricular remodeling following acute and subacute myocardial infarction (MI).

To determine the optimum mechanical properties of the GPAP, the researchers developed a computer model of the beating heart of a rat, which captured the mechanical dynamics of both the heart itself and the patch when fixed to the heart's exterior. After analyzing simulated modelling data, the researchers developed a GPAP with a low dynamic modulus that provided nearly optimal mechanical support to the remaining cardiomyocytes. The patch also outperformed other patches whose mechanical properties had been selected on an ad hoc basis. The study was published on April 15, 2019, in Nature Biomedical Engineering.

“Part of the reason that it's hard for the heart to recover after a heart attack is that it has to keep pumping. The idea here is to provide mechanical support for damaged tissue, which hopefully gives it a chance to heal,” said senior author professor of engineering Huajian Gao, PhD, of Brown University. “It remains to be seen if it will work in humans, but it's very promising. We don't see any reason right now that it wouldn't work.”

Cardiomyocytes carry out the contractile function of the heart, and the majority of them are terminally differentiated post-mitotic cells that exhibit very limited regenerative potential, and as a result the heart has insufficient regenerative capacity after injury or in diseased states, such as after a MI.

Related Links:
Brown University
Fudan University
Soochow University


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.